FDA Approves First Treatment For Rare Disease In Patients Who Receive Stem Cell Transplant From Blood Or Bone Marrow
- Amanda Bridges
- April 25, 2016
- Drugs
The U. S. Food and Drug Administration approved Defitelio (defibrotide sodium, Jazz Pharmaceuticals, Inc.) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
More Information: http://www.fda.gov/Drugs/
